Together, research suggests that concurrent TP53 and RB1 loss can potentially transform lung cancer cells away from their NSCLC (adenocarcinoma) differentiation lineage roots and become more SCLC-like in an effort to resist continuous targeted drug treatment. This evidence concerns the gene TP53 and small cell lung carcinoma.